AHA Post Conference Perspectives: Emerging Therapies in Hypertrophic Cardiomyopathy (HCM)

home / post-conference-perspectives / aha-post-conference-perspectives-emerging-therapies-in-hypertrophic-cardiomyopathy-hcm-

An expert in the management of hypertrophic cardiomyopathy discusses the burden of disease, existing treatment options, unmet needs, and explores data from an emerging class of agents, myosin inhibitors.

© 2023 MJH Life Sciences
AJMC®
All rights reserved.